Flatiron Health

AI is a transformative force in oncology, enabling scale, speed, and novel insights that were previously impossible. Our research at #ISPORAnnual validated AI’s ability to unlock real-world response data across tumor types—accelerating and streamlining clinical research for the benefit of patients everywhere. 📹 Hear from Senior Clinical Director Kelly Magee in a recent interview with The Evidence Base to learn more: https://lnkd.in/e__EQkmW

New today: Flatiron Health will be at #ASCO25 with 14 abstracts leveraging our high-quality real-world data. Our research delivers actionable evidence and answers questions for people with cancer that were once out of reach. Visit us at Booth #11131 or schedule a meeting with one of our experts: https://spkl.io/6041fNy71

At NHS ConfedExpo 2025, Adam Manhi will join Flatiron Health UK’s NHS partners to discuss how we transform routinely collected hospital data into high-quality datasets, enabling pioneering cancer research and improving patient outcomes and experience in the UK. ⭐ Hear from this group of experts live on June 11 at 1:30PM onsite at Manchester Central or find Flatiron team at booth #G31 anytime throughout the conference.

Meet Stephen Speicher, M.D., M.S., one of the Educational Summit & Program Chairs for #AVBCC2025.    As we approach this year’s conference, Dr. Speicher shares what he’s looking forward to and which topics he thinks will be top of mind as we navigate the ever-changing healthcare landscape.   Be sure to join us this October 22 - 24, 2025 at the New York Athletic Club for #AVBCC2025. Request your invitation: https://bit.ly/4bQpidk   #HealthcareLeaders #Cancer #ValueBasedCancerCare #OncologySummit #HealthcareConference

As a clinician who still sees patients and thinks A LOT about how #RWD and #AI can improve cancer care, I’m acutely aware of the importance of data quality. That’s why it’s so validating to see the results of this research presented by Vivek Verma, BDS, PhD and his team at #ISPORAnnual. This comprehensive framework evaluated different data sources across six key dimensions: relevance, reliability, extensiveness, timeliness, coherence, and convenience. The results are a testament to the hard work and attention Flatiron Health gives to data quality and ensuring decisions that impact patients are as correctly informed as possible. If you’re interested in learning how Flatiron’s multinational oncology data assets and expertise can help you feel free to DM me or reach out to chat: https://lnkd.in/ediwtzBQ Read the abstract here: https://lnkd.in/epxaPqHN Blythe Adamson, PhD, MPH Melissa Estevez

Is AI technology finally helping reduce the burnout that plagues healthcare? Stephen Speicher, M.D., M.S., Head of Clinical Oncology and Safety with our partners at Flatiron Health, believes so: "We're finally able to see technology keep up with the pace of change... This idea of burnout is so overwhelming. For the first time, technology has a true opportunity to impact burnout." "Our practices are so ready... to lean into artificial intelligence because they see this as their opportunity to make meaningful change in something that they're really scared about." In this interview with AJMC - The American Journal of Managed Care, Dr. Speicher and Flatiron Health Head of Product Kate Estep discuss the potential benefits that AI technology brings to the world of oncology. Kate notes the integration of #DeepScribe with Flatiron's OncoEMR® system: "We talk a lot about how you weave in the promise of ambient dictation... new AI technology that actually allows clinicians to start to look at 'what does invisible technology actually feel like.'" Check out the full interview, recorded at the recent Community Oncology Alliance conference, and follow DeepScribe for regular insights on how ambient intelligence benefits oncologists, and what's to come. (Related note: The latest readout from Stanford Medicine shows rates of physician burnout dipping - now 45.2% - but immensely higher than rates for the general population of workers.) #oncology #cancercare #ambientAI #physicianwellbeing #teamwork https://lnkd.in/e9YASTw9

Unlocking insights at scale: Flatiron’s Panoramic data solutions enable researchers to access longitudinal, real-world oncology data across diverse patient populations. 🎥 Hear from Emily Castellanos on how Panoramic datasets are unlocking our entire network of over five million people with cancer and powering the largest real-world studies to date. Learn more about our abstracts and events at #ASCO25: https://lnkd.in/eSTZDEMD

Flatiron Health is excited to present eight abstracts accepted for poster presentation this week at ISPOR—The Professional Society for Health Economics and Outcomes Research’s #ISPORAnnual. Highlights include: - a poster presentation validating the use of ML to extract real-world response from unstructured data in the EHR, offering a scalable and efficient method for generating high-quality oncology RWD - a poster presentation highlighting the acceptance of real-world evidence by the FDA and the EMA, underscoring its potential to complement traditional clinical trial data - a poster presentation introducing the Flatiron Health Japan Breast Cancer dataset, a novel, de-identified real-world database derived from structured and unstructured data collected from routine oncology care and stored within EHR systems in Japan Schedule time with our team onsite or visit us at booth #601 to learn more: https://lnkd.in/eiNd5XDF

More than a decade after the pivotal GOG-0218 and ICON7 trials, the treatment landscape for epithelial ovarian cancer (EOC) has evolved—but questions remain about how best to personalize care. Recent Flatiron Health research leverages real-world data to understand the impact of adding bevacizumab to first-line chemotherapy for patients with stage III/IV EOC. The findings reinforce what clinical trials suggested: the benefit of bevacizumab may be limited to patients with high-risk clinical factors, such as stage IV disease or stage III disease with residual tumor or no surgery. 🔍 By validating trial results in a real-world setting, this study helps clinicians make more informed, evidence-based decisions. It highlights the importance of tailoring treatment strategies based on individual risk profiles—bringing us one step closer to more personalized, effective care for ovarian cancer patients. Learn more about why this matters: https://spkl.io/6047fFl8t

Curious how pragmatic design can make your clinical studies more efficient and relevant? Join us next Monday, May 12 for a live webinar where a group of experts from across the industry will break down what works—and what doesn’t—in real-world oncology research. Bring your questions! Register here: https://spkl.io/6041f0SW7